PT-141 (Bremelanotide) 10mg

Description

Bremelanotide (PT-141) is a synthetic melanocortin receptor agonist that has been investigated for its ability to enhance sexual desire and arousal. In clinical research it produced statistically significant increases in sexual desire and reductions in distress related to low desire in premenopausal women; additional preclinical and clinical studies have explored its effects on male sexual function (erectile/sexual arousal). PT-141 acts centrally via melanocortin pathways and is used as a research reagent to study neuroendocrine control of sexual behavior and related signaling.

NOTE: Bremelanotide is not approved for all indications. It is an FDA-approved prescription product (Vyleesi®) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — product pages here are for research/experimental use only.

Key Research Uses & Findings

• Investigated as a centrally acting stimulant of sexual desire and arousal in humans and animal models.

• Studied as a potential treatment for hypoactive sexual desire disorder in premenopausal women (approved formulation available as Vyleesi®).

• Explored in male sexual-function research; studies report increased erectile activity and sexual responsiveness in some trials.

• Useful in mechanistic research probing melanocortin receptor (MC4R) signaling, dopaminergic pathways, and neural circuits that regulate sexual motivation.

Mechanism (summary)

Bremelanotide is a melanocortin receptor agonist with activity at receptors in the central nervous system (notably MC4R). Activation of these pathways is believed to influence dopaminergic signaling in hypothalamic regions involved in sexual motivation and arousal, producing centrally mediated increases in desire and related behaviors.

Safety & Tolerability (research context)

Common, treatment-emergent effects reported in human studies include nausea, flushing, headache, and transient increases in blood pressure. These effects are dose-dependent and were the most frequently observed adverse events in clinical trials. Researchers should monitor tolerability and cardiovascular parameters in in-vivo experiments and follow institutional safety protocols.

Recommended Research Usage

• In Vitro (cell assays / receptor studies): 1–1,000 nM (titrate to assay sensitivity and receptor expression).

• In Vivo (rodent studies): published preclinical ranges vary — follow established protocols and institutional animal-care guidelines; do not use clinical human dosing regimens for animals without validated conversion and IACUC approval.

• Handling: Reconstitute in sterile water or appropriate buffer immediately prior to use. Avoid repeated freeze–thaw cycles; prepare working solutions fresh.

• Formulation: For behavioral studies use validated routes (typically subcutaneous or intraperitoneal in animal models) per protocol.

Packaging & Storage

• Packaging: 10 mg amber glass vial with desiccant.

• Shelf Life: Up to 12 months unopened (confirm with COA).

• Storage: Store at −20 °C for long term; 2–8 °C acceptable short term. Protect from light and moisture; avoid repeated freeze–thaw cycles.

For laboratory and research use only. Not for human or veterinary consumption.
Do not market or label this product with clinical claims. If your work involves potential clinical applications, consult regulatory guidance and the approved product labeling.